CN106109408A - Topiramate slow release suspendible oral liquid and preparation method thereof - Google Patents
Topiramate slow release suspendible oral liquid and preparation method thereof Download PDFInfo
- Publication number
- CN106109408A CN106109408A CN201610503261.4A CN201610503261A CN106109408A CN 106109408 A CN106109408 A CN 106109408A CN 201610503261 A CN201610503261 A CN 201610503261A CN 106109408 A CN106109408 A CN 106109408A
- Authority
- CN
- China
- Prior art keywords
- topiramate
- slow
- release
- preparation
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of slow release suspendible oral liquid containing topiramate and preparation method thereof.The preparation of the present invention includes the compositions such as topiramate, ion exchange resin, coating material, suspending agent, plasticizer, preservative, correctives.Preparation technology includes preparing drug-resin complex, pastille resin complexes and other additives is mixed with and obtains slow-release suspension.The topiramate slow releasing preparation that the present invention provides uses ion exchange technique, can cover the bad mouthfeel of topiramate, be simultaneously manufactured liquid preparation, it is simple to the patient of dysphagia takes, significantly improve the compliance of patient.The topiramate slow releasing preparation that the present invention provides, takes rear blood drug level steady, and blood drug level, between quick releasing formulation peak concentration and peak valley concentration, can effectively control the outbreak of epilepsy, reduces rate of side effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation treating epilepsy and preparation method thereof, belong to neurosurgery class disease medication,
It is specifically related to a kind of topiramate slow-release suspension and preparation method thereof.
Background technology
Topiramate is a kind of wide spectrum Newer antiepileptic, has multiple antiepileptic action mechanism, all has each pyknolepsy
Effect, is wherein especially apparent constitutional, the outbreak of Secondary cases generalized tonic-clonic and simple or complex partial seizure effect.To flesh battle array
Contraction, infantile spasm are the most effective.But its treatment window is the narrowest, blood concentration fluctuation can produce a lot of side effect, therefore suffers from for improving
Person's compliance and clinical administration need, and are made generally in slow releasing preparation.
Topiramate chemistry entitled 2,3:4, double-O-(1-methyl the ethylidene)-Beta-D-Fructopyranose sulfamate of 5-, tie for white
Crystalline flour end, bitter in the mouth pole, it is soluble in acetone, dimethyl sulfoxide, ethanol and the alkaline solution comprising sodium hydroxide or sodium phosphate, room temperature
Its dissolubility in water lower only has about 9.8mg/mL, and the pH value of its saturated solution is 6.3, fusing point: 125-126 DEG C.Structural formula
As follows:
。
CN1988889 discloses a kind of Sustained-release topiramate preparation and the method for preparation topiramate formulation, described slow release torr pyrrole
Ester formulation uses secondary granulating process to be prepared, and it is to be prepared by solid dispersion method that wherein said secondary is pelletized.Use solid
Dispersant, by topiramate or its pharmaceutically acceptable salt particle (first granulation), uses slow-release material by described further
Grain granulating (secondary granulation) obtains.The solid dispersion method used is fusion method, and preparation process needs high-temperature heating, is easily caused
Medicine decomposes or has related substance to increase.
CN1905857 discloses the dosage form of a kind of controlled-release delivery topiramate liquid preparation.Disclosed dosage form includes one
Semipermeable wall, medicine layer, barrier layer and an expandable layer, and barrier layer is formed at capsule with coating form
On.Preparation technology is more complicated.
Summary of the invention
It is an object of the invention to provide a kind of topiramate slow release suspendible oral liquid, this oral liquid can be taken by divided dose, special
The epileptic not being suitable for dysphagia takes, and improves the Compliance of patient.Can effectively control again to delay medicine at body
Interior absorption, blood drug level is steady, persistent, stable curative effect.
Described slow release suspendible oral liquid, effective ingredient is topiramate, also includes coating material, plasticizer, suspending agent, prevents
Rotten agent, correctives etc..Wherein topiramate is made composite particles by topiramate and ion exchange resin, and topiramate and ion exchange
The weight ratio of resin is 1:4-1:8, it is preferable that 1:6.Described medical resin composite particles particle diameter is 10 ~ 40 mesh.
Described ion exchange resin include styrene strong acidic ion resin, styrene acidulous cation resin,
Polystyrene Sulfonate sodium ionomer resin, acrylic or methacrylic acid acidulous cation resin one or more.Preferably
Polystyrene Sulfonate sodium ionomer resin.
Described coating material includes that methacrylate copolymer, ethyl cellulose, hydroxypropyl cellulose, carboxymethyl are fine
Dimension element, sodium carboxymethyl cellulose, cellulose acetate, hydroxyethyl cellulose, HP-55, polyvinyl acetate,
Polyacrylic resin therein one or more.
Described topiramate slow-release suspension, it is characterised in that described suspending agent includes carbomer, hydroxypropyl methyl fiber
Element, microcrystalline Cellulose, colloidal silica, xanthan gum, sodium carboxymethyl cellulose, pectin, arabic gum, gelatin, tragcanth
One or more mixture therein.
Described plasticizer includes propylene glycol, glycerol, Oleum Ricini, liquid paraffin, triacetin, phthalic acid two fourth
Ester, Polyethylene Glycol, diethyl phthalate therein one or more.
Described preservative include methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, sorbic acid, potassium sorbate, benzoic acid and
Sodium salt, chlorobutanol therein one or more.Being preferably hydroxypropyl ethyl ester, consumption is 0.1% ~ 0.5%(w/v).
Described correctives include sweeting agent and essence, described sweeting agent include aspartame, saccharin sodium, stevioside,
Sucralose, sucrose and sorbitol therein one or more；Preferably sucrose and sorbitol, sucralose and saccharin sodium, front
Person's consumption is 20% ~ 40%(w/v)；The latter's consumption is 0.5% ~ 1%(w/v).Described essence be fragrant citrus, Fructus Citri sinensis, Fructus Fragariae Ananssae, blue berry,
Black currant, Fructus Vitis viniferae, Herba Menthae therein one or more.Being preferably orange taste, blue berry and Fructus Fragariae Ananssae, consumption is 0.05% ~ 0.1%(w/v).
The preparation method of topiramate slow release suspendible oral liquid of the present invention concretely comprises the following steps:
(1) prepared by topiramate ion exchange resin complexes: add ion exchange resin to the blender equipped with deionized water
In, under stirring, add medicine to standing after adsorption equilibrium, filtering, abandon filtrate collection filtrate, be dried, cross 10 ~ 40 mesh
Sieve, obtains topiramate ion exchange resin complexes microgranule；
(2) prepared by sustained-release microparticle: is scattered in coating material and plasticizer solution by compound particles obtained above, sprays
Mist is dried, and crosses 20 ~ 50 mesh sieves, obtains topiramate sustained-release microparticle；
(3) prepared by slow-release suspension: by the above-mentioned topiramate sustained-release microparticle prepared and suspending agent, preservative, correctives, stir
Mix mix homogeneously, obtain topiramate slow-release suspension.
Topiramate slow release suspendible oral liquid provided by the present invention, uses ion exchange resin inclusion medicine, and uses slow
Release coating material to be coated, have effectively achieved the slow releasing function of medicine, add the additives such as suspending agent, correctives and prepare
Become suspension.Can take by divided dose, good mouthfeel, improve the Compliance of patient, and technique is simple, cost is relatively low, suitable
Together in industrialized production.
Specific embodiment
Being further elaborated with the present invention by following example, embodiment is only used for the purpose of illustration, this
Bright scope is not limited to these embodiments:
Embodiment 1
The prescription composition of 500ml topiramate slow release suspendible oral liquid:
| Supplementary material | Weight (g) |
| Topiramate | 10.00 |
| Polystyrene Sulfonate sodium ionomer resin | 80.00 |
| Polyacrylic resin | 40.00 |
| Propylene glycol | 1.50 |
| Xanthan gum | 5.00 |
| Ethyl hydroxybenzoate | 2.50 |
| Sucrose | 200.0 |
| Sucralose | 5.00 |
| Orange essence | 0.500 |
| Pure water | 500.0 |
Preparation technology:
(1) preparation of topiramate ion exchange resin composite particles: recipe quantity polystyrene Sulfonate sodium ionomer resin is added to dress
Having in the blender of deionized water, rotating speed is 500rpm, is gradually added into topiramate under stirring, continuously stirred 3h, to from
Stand after son exchange exchange equilibrium, filter, abandon filtrate collection filtrate, 50 DEG C of air dry ovens are dried, be dried after terminating, multiple
Close microgranule and cross 10 ~ 40 mesh sieves, obtain topiramate ion exchange resin complexes microgranule；
(2) prepared by sustained-release microparticle: stirring is lower adds the compound particles of recipe quantity, polyacrylic resin coating material, propylene glycol
Joining in 50% ethanol solution, making concentration is 30%, 500rpm, and continuously stirred 1h, to being uniformly dispersed, is spray-dried, spray
Mist is dried intake air temperature 100～110 DEG C, air outlet temperature 70 C, air exhauster power 100%, constant flow pump pump speed 10.0
mlmin-1.Collect sample and cross 20 ~ 50 mesh sieves, obtain topiramate sustained-release microparticle；
(3) prepared by slow-release suspension: the ethyl hydroxybenzoate weighing recipe quantity dissolves in 90 DEG C of heating in water bath, is cooled to room temperature and adds successively
Enter propylene glycol, xanthan gum, sucrose, sucralose and orange essence etc., stir, fully mix, be incorporated in the topiramate bag of place's equivalent
The continuously stirred 3h of clothing microgranule, to mix homogeneously, is eventually adding pure water to 500ml, stirs, obtain topiramate slow release suspendible
Liquid.
Embodiment 2
The prescription composition of 500ml topiramate slow release suspendible oral liquid:
| Supplementary material | Weight (g) |
| Topiramate | 10.00 |
| Polystyrene Sulfonate sodium ionomer resin | 60.00 |
| Polyacrylic resin | 40.00 |
| Propylene glycol | 2.50 |
| Xanthan gum | 5.00 |
| Ethyl hydroxybenzoate | 2.50 |
| Sucrose | 150.0 |
| Sucralose | 3.50 |
| Blueberry flavor | 0.500 |
| Pure water | 500.0 |
Preparation technology:
(1) preparation of topiramate ion exchange resin composite particles: recipe quantity polystyrene Sulfonate sodium ionomer resin is added to dress
Having in the blender of deionized water, rotating speed is 500rpm, is gradually added into topiramate under stirring, continuously stirred 3h, to from
Stand after son exchange exchange equilibrium, filter, abandon filtrate collection filtrate, 50 DEG C of air dry ovens are dried, be dried after terminating, multiple
Close microgranule and cross 10 ~ 40 mesh sieves, obtain topiramate ion exchange resin complexes microgranule；
(2) prepared by sustained-release microparticle: stirring is lower adds the compound particles of recipe quantity, polyacrylic resin coating material, propylene glycol
Joining in 50% ethanol solution, making concentration is 30%, 500rpm, and continuously stirred 1h, to being uniformly dispersed, is spray-dried, spray
Mist is dried intake air temperature 100～110 DEG C, air outlet temperature 70 C, air exhauster power 100%, constant flow pump pump speed 10.0
mlmin-1.Collect sample and cross 20 ~ 50 mesh sieves, obtain topiramate sustained-release microparticle；
(3) prepared by slow-release suspension: the ethyl hydroxybenzoate weighing recipe quantity dissolves in 90 DEG C of heating in water bath, is cooled to room temperature and adds successively
Enter propylene glycol, xanthan gum, sucrose, sucralose and blueberry flavor etc., stir, fully mix, be incorporated in the topiramate of place's equivalent
The continuously stirred 3h of coated particle, to mix homogeneously, is eventually adding pure water to 500ml, stirs, obtain topiramate slow release suspendible
Liquid.
Embodiment 3
The prescription composition of 500ml topiramate slow release suspendible oral liquid:
| Supplementary material | Weight (g) |
| Topiramate | 10.00 |
| Polystyrene Sulfonate sodium ionomer resin | 40.00 |
| Polyacrylic resin | 40.00 |
| Propylene glycol | 2.50 |
| Xanthan gum | 5.00 |
| Ethyl hydroxybenzoate | 2.50 |
| Sucrose | 100.0 |
| Sucralose | 2.50 |
| Strawberry essence | 0.500 |
| Pure water | 500.0 |
Preparation technology:
(1) preparation of topiramate ion exchange resin composite particles: recipe quantity polystyrene Sulfonate sodium ionomer resin is added to dress
Having in the blender of deionized water, rotating speed is 500rpm, is gradually added into topiramate under stirring, continuously stirred 3h, to from
Stand after son exchange exchange equilibrium, filter, abandon filtrate collection filtrate, 50 DEG C of air dry ovens are dried, be dried after terminating, multiple
Close microgranule and cross 10 ~ 40 mesh sieves, obtain topiramate ion exchange resin complexes microgranule；
(2) prepared by sustained-release microparticle: stirring is lower adds the compound particles of recipe quantity, polyacrylic resin coating material, propylene glycol
Joining in 50% ethanol solution, making concentration is 30%, 500rpm, and continuously stirred 1h, to being uniformly dispersed, is spray-dried, spray
Mist is dried intake air temperature 100～110 DEG C, air outlet temperature 70 C, air exhauster power 100%, constant flow pump pump speed 10.0
mlmin-1.Collect sample and cross 20 ~ 50 mesh sieves, obtain topiramate sustained-release microparticle；
(3) prepared by slow-release suspension: the ethyl hydroxybenzoate weighing recipe quantity dissolves in 90 DEG C of heating in water bath, is cooled to room temperature and adds successively
Enter propylene glycol, xanthan gum, sucrose, sucralose and strawberry essence etc., stir, fully mix, be incorporated in the topiramate of place's equivalent
The continuously stirred 3h of coated particle, to mix homogeneously, is eventually adding pure water to 500ml, stirs, obtain topiramate slow release suspendible
Liquid.
By the topiramate slow release suspendible oral liquid of the present invention with the former topiramate capsule that grinds according to dissolution method (2015
Version " Chinese Pharmacopoeia " general rule 0,931 first method and the second method) carry out topiramate stripping curve and compare:
Topiramate slow release suspendible oral liquid grinds the contrast of topiramate capsule stripping curve with former
| Dissolution (%) | Embodiment 1 | Embodiment 2 | Embodiment 3 | Commercially available control formulation |
| 1h | 17.54 | 21.28 | 24.42 | 20.21 |
| 4h | 42.35 | 47.86 | 57.85 | 45.32 |
| 8h | 64.45 | 76.27 | 82.28 | 70.25 |
| 12h | 82.85 | 91.34 | 99.35 | 85.12 |
| 16h | 90.57 | 95.26 | 99.49 | 95.25 |
| 20h | 95.52 | 97.42 | 100.21 | 99.54 |
Visible, topiramate slow release suspendible oral liquid (embodiment 1,2,3) In Vitro Dissolution of the present invention is along with sodium polystyrene sulfonate
Ion exchange resin consumption reduce slow release effect weaken, wherein embodiment 1 In Vitro Dissolution effect with former grind capsule compared with difference less, release
Let pass as similar.
Claims (10)
1. a topiramate slow-release suspension, effective ingredient is topiramate, also includes ion exchange resin, coating material, suspending
Agent, plasticizer, preservative, correctives are at interior raw material components, it is characterised in that described topiramate is formed with ion exchange resin
Composite particles, and the weight ratio of topiramate and ion exchange resin is 1:4 ~ 1:8.
2. topiramate slow-release suspension as claimed in claim 1, it is characterised in that the particle diameter of described composite particles is 10 ~ 40
Mesh.
3. the topiramate slow-release suspension as described in claim 1, it is characterised in that described ion exchange resin includes benzene second
Alkene strong acidic ion resin, styrene acidulous cation resin, polystyrene Sulfonate sodium ionomer resin, acrylic acid or methyl-prop
One or more mixture in olefin(e) acid acidulous cation resin.
4. the topiramate slow-release suspension as described in claim 1, it is characterised in that described coating material includes metering system
Acid ester copolymer, ethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose acetate, hydroxyl
Ethyl cellulose, HP-55, polyvinyl acetate, polyacrylic resin therein one or more.
5. the topiramate slow-release suspension as described in claim 1, it is characterised in that described suspending agent includes carbomer, hydroxypropyl
Ylmethyl cellulose, microcrystalline Cellulose, colloidal silica, xanthan gum, sodium carboxymethyl cellulose, pectin, arabic gum, bright
Glue, tragcanth one or more mixture therein.
6. the topiramate slow-release suspension as described in claim 1, it is characterised in that described plasticizer include propylene glycol, glycerol,
Oleum Ricini, liquid paraffin, triacetin, dibutyl phthalate, Polyethylene Glycol, diethyl phthalate are therein
One or more.
7. the topiramate slow release suspendible oral liquid as described in claim 1, it is characterised in that described preservative includes oxybenzene first
Ester, ethyl hydroxybenzoate, propyl hydroxybenzoate, sorbic acid, potassium sorbate, benzoic acid and sodium benzoate, chlorobutanol one therein or one
More than Zhong.
8. the topiramate slow-release suspension as described in claim 1, it is characterised in that described correctives includes sweeting agent and perfume (or spice)
Essence, described sweeting agent is selected from aspartame, saccharin sodium, stevioside, sucralose, sucrose and sorbitol one therein or several
Plant mixture；Described essence is fragrant citrus, Fructus Citri sinensis, Fructus Fragariae Ananssae, blue berry, black currant, Fructus Vitis viniferae, Herba Menthae one or more mixed therein
Compound.
9. according to the preparation method of the topiramate slow-release suspension described in claim 1 ~ 6 any one, it is characterised in that:
(1) prepare medical resin microgranule: first prepare topiramate drug solution, be subsequently adding ion exchange resin stirring, carry out
Ion exchanges, and exchange is filtered after terminating, and uses deionized water to wash away free drug, is dried, obtains composite particles；
(2) prepared by sustained-release microparticle: is scattered in coating material and plasticizer solution by composite particles obtained above, sprays
It is dried, obtains topiramate sustained-release microparticle；
(3) prepared by slow-release suspension: stirred with suspending agent, preservative, correctives by the above-mentioned topiramate sustained-release microparticle prepared
Mix mix homogeneously, obtain topiramate slow-release suspension.
10. the preparation method of topiramate slow-release suspension as claimed in claim 9, it is characterised in that topiramate sustained-release microparticle mistake
20 ~ 50 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610503261.4A CN106109408A (en) | 2016-07-01 | 2016-07-01 | Topiramate slow release suspendible oral liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610503261.4A CN106109408A (en) | 2016-07-01 | 2016-07-01 | Topiramate slow release suspendible oral liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109408A true CN106109408A (en) | 2016-11-16 |
Family
ID=57285707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610503261.4A Pending CN106109408A (en) | 2016-07-01 | 2016-07-01 | Topiramate slow release suspendible oral liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106109408A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553416A (en) * | 2018-06-14 | 2018-09-21 | 五邑大学 | A kind of sustained release mixed suspension preparation and preparation method thereof containing levodopa and benserazide hydrochloride |
| WO2020104837A1 (en) * | 2018-11-21 | 2020-05-28 | Rosemont Pharmaceuticals Limited | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
| US11433046B2 (en) | 2019-12-10 | 2022-09-06 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824302A (en) * | 2011-06-14 | 2012-12-19 | 杭州赛利药物研究所有限公司 | Topiramate sustained release preparation and preparation method thereof |
| CN105310980A (en) * | 2015-10-09 | 2016-02-10 | 北京万全德众医药生物技术有限公司 | Paliperidone controlled-release suspension oral liquid and its preparation method |
| CN105663038A (en) * | 2016-02-03 | 2016-06-15 | 北京诺康达医药科技有限公司 | Liquid slow-release preparation and preparation method thereof |
-
2016
- 2016-07-01 CN CN201610503261.4A patent/CN106109408A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824302A (en) * | 2011-06-14 | 2012-12-19 | 杭州赛利药物研究所有限公司 | Topiramate sustained release preparation and preparation method thereof |
| CN105310980A (en) * | 2015-10-09 | 2016-02-10 | 北京万全德众医药生物技术有限公司 | Paliperidone controlled-release suspension oral liquid and its preparation method |
| CN105663038A (en) * | 2016-02-03 | 2016-06-15 | 北京诺康达医药科技有限公司 | Liquid slow-release preparation and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553416A (en) * | 2018-06-14 | 2018-09-21 | 五邑大学 | A kind of sustained release mixed suspension preparation and preparation method thereof containing levodopa and benserazide hydrochloride |
| WO2020104837A1 (en) * | 2018-11-21 | 2020-05-28 | Rosemont Pharmaceuticals Limited | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
| US11433046B2 (en) | 2019-12-10 | 2022-09-06 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
| US11633374B2 (en) | 2019-12-10 | 2023-04-25 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
| US11826343B2 (en) | 2019-12-10 | 2023-11-28 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
| US11911362B2 (en) | 2019-12-10 | 2024-02-27 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108601791A (en) | Method for crystallising and bioavilability | |
| CN104586775B (en) | Astragalus polysaccharide sustained release microsphere for treating radiation pneumonitis and preparation method of astragalus polysaccharide sustained release microsphere | |
| CN101563295B (en) | Iron (III)-carbohydrate based phosphate adsorbent | |
| KR20180006904A (en) | Formulation of L-ornithine phenylacetate | |
| US20130004563A1 (en) | Multiparticulate s-adenosylmethionine compositions and related methods | |
| JP6656316B2 (en) | How to use cucumbers, how to use cucumbers extract and how to use drug mixtures | |
| CN106109408A (en) | Topiramate slow release suspendible oral liquid and preparation method thereof | |
| CN103565941B (en) | A kind of Radix Et Rhizoma Rhei anthraquinone oral colon-target administration composition and uses thereof | |
| CN101095670B (en) | Luteolin phospholipid complexes and method for preparing the same and application thereof | |
| KR20170125992A (en) | Silivin, VE and carnitine-containing pharmaceutical compositions | |
| CN102772802A (en) | Oleanolic acid nanoliposome modified by chitosan and polyethylene glycol and preparation method thereof | |
| CN112870371A (en) | Application of cyclodextrin-metal organic framework in preparation of inhalant and inhalant | |
| WO2021184639A1 (en) | Microcapsule preparation for eliminating food stagnation and relieving coughs in children and preparation method therefor | |
| PT90308B (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING AZELASTIN WITH CONTROLLED LIBERTACAOUS ACTIVE SUBSTANCE | |
| KR101616134B1 (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| CN106474129A (en) | Composition of XiLin or its pharmaceutically acceptable salt and pharmaceutic adjuvant and preparation method thereof won by a kind of handkerchief | |
| CN104138376A (en) | A sustained release agent improving anoxia endurance | |
| CN104940167B (en) | A kind of preparation method for loading berberine phosphatide composite nano particle | |
| CN100562322C (en) | Colon targeting preparation of a kind of 5-aminosalicylic acid and preparation method thereof | |
| CN104771375B (en) | A kind of Dronedarone hydrochloride tablet and preparation method thereof | |
| CN103860464A (en) | Antiallergic drug sustained release suspension and preparation method of suspension | |
| CN108283628A (en) | A kind of anticancer drug microcapsule formulation and preparation method thereof | |
| CN104306330A (en) | Memantine hydrochloride slow-release suspension and preparation method thereof | |
| CN102058529A (en) | Oral liquid slow-release preparation containing ondansetron and preparation method thereof | |
| CN101658507A (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |
|
| RJ01 | Rejection of invention patent application after publication |